Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 8
Submit an article Journal homepage
104
Views
3
CrossRef citations to date
0
Altmetric
Drug Evaluations

Novel antiarrhythmic drugs in atrial fibrillation: focus on tedisamil

Suresh Krishnamoorthy City Hospital, University Department of Medicine, Centre for Cardiovascular Sciences, Birmingham, B18 7QH, UK +44 121 507 5080; +44 121 507 5907; [email protected]
, MRCP &
Gregory YH Lip City Hospital, University Department of Medicine, Centre for Cardiovascular Sciences, Birmingham, B18 7QH, UK +44 121 507 5080; +44 121 507 5907; [email protected]
, MD
Pages 1191-1196 | Published online: 15 Jul 2009

Bibliography

  • Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5
  • Hagens VE, Ranchor AV, Van Sonderen E, et al.; RACE Study Group. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation: results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol 2004;43:241-7
  • Wachtell K, Hornestam B, Lehto M, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) Study. J Am Coll Cardiol 2005;45:705-11
  • Wyse DG, Waldo AL, Dimarco JP, et al.; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33
  • Roy D, Talajic M, Nattel S, et al.; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-77
  • Chung MK, Shemanski L, Sherman DG, et al.; AFFIRM Investigators. Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy. J Am Coll Cardiol 2005;46:1891-9
  • Corley SD, Epstein AE, Dimarco JP, et al.; AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004;109:1509-13
  • Lafuente-lafuente C, Mouly S, Longás-tejero MA, et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 2006;166:719-28
  • Honnloser SH, Crijns HJ, van Eickels M, et al.; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78
  • DIONYSOS study results showed the respective profiles of dronedarone and amiodarone. Press release, Sanofi-aventis. Available from: http://en.sanofi-aventis.com/binaries/20081223_dionysos_fe_ en_en_tcm28-23624.pdf
  • Page RL, Tilsh TW, Connolly SJ, et al: Pritchett EL for the Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators. Asymptomatic or ‘silent’ atrial fibrillation: frequency in untreated patients and patients receiving azimilide. Circulation 2003;107:1141-5
  • Pritchett EL, Kowey P, Connolly S, et al: Wilkinson WE for the A-COMET-I Investigators. Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation: maintenance of sinus rhythm after conversion to sinus rhythm. Am Heart J 2006;151:1043-9
  • Kerr CR, Connolly SJ, Kowey P, et al: Wilkinson WE for the A-STAR Investigators. Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence or absence of structural heart disease. Am J Cardiol 2006;98:215-8
  • Roy D, Rowe BH, Stiell IG, et al: Craft Investigators. A randomised, controlled trial of RSD 1235, a novel antiarrhythmic agent in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004;44:2355-61
  • Pratt C, Roy D, Juul-Moller S. Efficacy and tolerance of RSD 1235 in the treatment of atrial fibrillation or atrial flutter. Results of a Phase III, randomized, placebo-controlled, multicenter trial [abstract]. J Am Coll Cardiol 2006;47:10A
  • Mitrovic V, Oehm E, Liebrich A, et al. Hemodynamic and antiischemic effects of tedisamil in humans. Cardiovasc Drugs Ther 1992;6:353-60
  • Démolis JL, Martel C, Funck-Brentano C, et al. Effects of tedisamil, atenolol and their combination on heart and rate-dependent QT interval in healthy volunteers. Br J Clin Pharmacol 1997;44:403-9
  • van Haarst AD, Dijkmans AC, Weimann HJ, et al. Clinically important interaction between tedisamil and verapamil. J Clin Pharmacol 2009;49:560-7
  • Oxle B, Weirich J, Antoni H. Electrophysiologic profile of KC8857, a new bradycardic agent. J Mol Cell Cardiol 1987;19:s65
  • Dukes ID, Morad M. The mode of action of tedisamil on voltage dependent K channels. Cardiovasc Drugs Ther 1992;6:321-7
  • Ravens U, Amos GJ, Li Q, Metzger F. Effects of antiarrhythmic agent tedisamil. Exp Clin Cardiol 1997;2:231-6
  • Wettwer E, Himmel HM, Amos GJ, et al. Mechanism of block by tedisamil of transient outward current in human ventricular subepicardial myocytes. Br J Pharmacol 1998;125:659-66
  • Nemeth M, Varro A, Thorma'hlen D, Papp J. Tedisamil is a potent blocker of ATP-sensitive potassium channels in cardiac muscle. Exp Clin Cardiol 1997;2:37-40
  • Baskin EP, Lynch JJ. Differential atrial versus ventricular activities of class III potassium channel blockers. J Pharmacol Exp Ther 1998;285:135-42
  • Faivre HF, Gout B, Bril A. Tedesamil. Cardiovasc Drug Rev 1995;13:33-50
  • Pfrunder D, Kreye VAW. Tedisamil blocks single large conductance ca2+ activated K+ channels in membrane patches from smooth muscle cells of the guinea pig portal vein. Pflugers Arch 1991;418:308-12
  • Bray K, Quast U. Differential inhibition by tedisamil (KC8857) and glibenclamide of the responses to cromakalin and minoxidil sulphate in rate isolated aorta. Nauynyn-Schmiedeberg's Arch Pharmacol 1992;345:244-50
  • Fischbach PS, Barrett TD, Goyal R, Tran BC. Conversion of atrial fibrillation by experimental antiarrhythmic drug tedisamil in two canine models. J Cardiovasc Electrophysiol 2001;12:1138-44
  • Fischbach PS, Johnston PV, Friedrichs GS, Lucchesi BR. Tedisamil in a chronic canine model of atrial flutter. J Cardiovas Pharmacol 1999;34:212-18
  • Beatch GN, Abraham S, Macleod BA, et al. Antiarrhythmic properties of tedisamil (KC8857), a putative transient outward K+ current blocker. Br J Pharmacol 1991;102:13-18
  • Bril A, Landais L, Gout B. Actions and interactions of E-4031 and tedisamil on reperfusion-induced arrhythmias and QT interval in rat in vivo. Cardiovasc Drugs Ther 1993;7:233-40
  • Tsuchihashi K, Curtis MJ. Influence of tedisamil on the initiation and maintenance of ventricular fibrillation: chemical defibrillation by Ito blockade? J Cardiovasc Pharmacol 1991;18:445-6
  • Adaikan G, Beatch GN, Lee TL, et al. Antiarrhythmic actions of tedisamil. Studies in rats and primates. Cardiovasc Drugs Ther 1992;6:345-52
  • Hohnloser SH, Dorian P, Straub M, et al. Safety and Efficacy of Intravenously Administered Tedisamil for Rapid Conversion of Recent-Onset Atrial Fibrillation or Atrial Flutter. J Am Coll Cardiol 2004;44:99-104
  • Vaughan-Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984;24:129-47
  • Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 1990;81:686-90
  • Duchosal F, Opie LH. Potential beneficial effects of potassium channel blockade by tedisamil in isolated perfused working rat heart with coronary artery ligation. Cardiovasc Drugs Ther 1992;6:329-36
  • Kuhl UG, Buschmann G. Cardiovascular profile of KC8857 in comparison to other cardioactive agents. J Mol cell Cardiol 1987;19:s50
  • Grohs JG, Fischer G, Raberger G. Cardiac and hemodynamic effects of the selective bradycardic agent KC8857 during exercise-induced myocardial ischemia. Eur J Pharmacol 1989;161:53-60
  • Raberger G, Gronhs JG, Fischer G. Anti-ischemic effects of tedisamil in conscious dogs. Cardiovasc Drugs Ther 1992;6:337-43
  • Fox KM, Henderson JR, Kaski JC, et al. Antianginal and anti-ischaemic efficacy of tedisamil, a potassium channel blocker. Heart 2000;83:167-71
  • Bargheer K, Bode F, Klein HU, et al. Prolongation of monophasic action potential duration and the refractory period in humans‘ heart by tedisamil, a new potassium-blocking agent. Eur Heart J 1994;15:1409-14
  • Hermann HP, Ohler A, Just H, Hasenfuss G. Cardiac and hemodynamic effects of the sinus node inhibitor tedisamil dihydrochloride in patients with congestive heart failure due to dilated cardiomyopathy. J Cardiovasc Pharmacol 1998;32:969-74
  • Food and Drug Administration Centre for Drug Evaluation and Research. Available from: www.fda.gov/OHRMS/DOCKETS/AC/07/minutes/2007-4327m-02-minutes-final-tedisamil-dec12.pdf

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.